|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Research, development and engineering expenses | |||||
| Selling, general and administrative expenses | |||||
| Recall charges, net | |||||
| Amortization of intangible assets | |||||
| Goodwill impairment | |||||
| Goodwill and other impairments | |||||
| Total operating expenses | |||||
| Operating income | |||||
| Interest expense | |||||
| Other income | |||||
| Earnings before income taxes | |||||
| Income taxes | |||||
| Net earnings | |||||
| Net earnings per share of common stock: | |||||
| Basic net earnings per share of common stock (in dollars per share) | |||||
| Diluted net earnings per share of common stock (in dollars per share) | |||||
| Weighted-average shares outstanding (in millions): | |||||
| Basic (in shares) | |||||
| Effect of dilutive employee stock compensation (in shares) | |||||
| Diluted (in shares) |
Loading...
